News >

Dual HER2 Blockade Superior for PFS in HER2+/HR+ Metastatic Breast Cancer

Jason Harris
Published: Friday, Dec 29, 2017

Stephen R.D. Johnston, PhD
Stephen R.D. Johnston, PhD
The combination of lapatinib (Tykerb), trastuzumab (Herceptin), and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer (MBC) compared with those treated with a targeted agent plus AI, according to findings published in the Journal of Clinical Oncology.

The most common any-grade adverse event (AE) in the triplet arm was diarrhea (69%), followed by rash (36%), nausea (22%), and  paronychia (30%). Investigators reported that the frequency of grade 3/4 AEs was <5% across the 3 treatment arms except for diarrhea in the lapatinib/trastuzumab plus AI arm (13%) and the lapatinib plus AI arm (6%).
Johnston SRD, Hegg R, Im S, et al. Phase III, Randomized study of dual human epidermal growth factor receptor 2 (her2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with her2-positive, hormone receptor–positive metastatic breast cancer: ALTERNATIVE [published online December 15, 2017]. J Clin Oncol doi: 10.1200/JCO. 2017.74.7824.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x